Companies › Shionogi
10 active drug programs in 30 registered trials: 11 Phase 1, 11 Phase 2, 5 Phase 4, 3 Phase 3; Respiratory, Infectious disease, Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Secutrelvir SARS-CoV-2 3CL protease inhibitor | 3CL | Phase 3 | COVID-19; SARS-CoV-2 | Jul 2027 |
| S-337395 RSV antiviral agent | – | Phase 2 | Respiratory Syncytial Virus Infections | Dec 2026 |
| Acetazolamide Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor | CA1, CA2, CA12, CA4 | Phase 2 | Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain … | Dec 2026 |
| SASS-001 | – | Phase 2 | Sleep Apnea | Dec 2026 |
| Sivopixant CRF1 receptor antagonist | CRHR1 | Phase 2 | Sleep Apnea | Dec 2026 |
| S-606001 Unclear - mechanism not specified | – | Phase 2 | Pompe Disease | Aug 2027 |
| Zatolmilast (BPN14770) Phosphodiesterase 4D inhibitor | PDE4D | Phase 2 | Jordan's Syndrome | Dec 2027 |
| S-531011 | – | Phase 1 | Solid Tumors | May 2028 |
| Naldemedine Mu opioid receptor antagonist | OPRM1 | Phase 1 | Opioid-Induced Constipation (OIC) | Jun 2028 |
| S-892216-LAI | – | Phase 1 | Healthy Participants | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05300477 | Acetazolamide | Phase 4 | Hypobaric Hypoxia | Other | Sep 2023 |
| NCT07118462 | Acetazolamide | Phase 4 | High Altitude Effects | Other | Dec 2025 |
| NCT05293600 | Acetazolamide | Phase 1 | Obstructive Sleep Apnea | Respiratory | Oct 2026 |
| NCT05804084 | Acetazolamide | Phase 2 | Obstructive Sleep Apnea | Respiratory | Oct 2026 |
| NCT07101250 | Acetazolamide | Phase 4 | Post Operative Pain | Other | Dec 2026 |
| NCT06981234 | Acetazolamide | Phase 2 | Type 1 Diabetes | Metabolic and endocrine | Dec 2026 |
| NCT03011671 | Acetazolamide | Phase 1 | Malignant Glioma of Brain | Oncology | Dec 2026 |
| NCT07214571 | S-337395 | Phase 2 | Respiratory Syncytial Virus Infections | Infectious disease | Dec 2026 |
| NCT06776432 | Sivopixant | Phase 2 | Sleep Apnea | Respiratory | Dec 2026 |
| NCT06776432 | Acetazolamide | Phase 2 | Sleep Apnea | Respiratory | Dec 2026 |
| NCT04118387 | Acetazolamide | Phase 4 | Sleep Disordered Breathing | Respiratory | Dec 2026 |
| NCT05589753 | Acetazolamide | Phase 1 | Sleep Apnea | Psychiatry | Dec 2026 |
| NCT06776432 | SASS-001 | Phase 2 | Sleep Apnea | Respiratory | Dec 2026 |
| NCT07372040 | Acetazolamide | Phase 2 | Acute Decompensated Heart Failure | Cardiovascular | Feb 2027 |
| NCT05470283 | Acetazolamide | Phase 1 | Tumor | Oncology | Apr 2027 |
| NCT03467360 | Acetazolamide | Phase 1 | Small Cell Lung Cancer | Oncology | Apr 2027 |
| NCT02703220 | Acetazolamide | Phase 4 | Sleep Apnea | Respiratory | Jul 2027 |
| NCT07746544 | Secutrelvir | Phase 3 | COVID-19 | Infectious disease | Jul 2027 |
| NCT07123155 | S-606001 | Phase 2 | Pompe Disease | Metabolic and endocrine | Aug 2027 |
| NCT06091085 | Acetazolamide | Phase 1 | OSA | Neurology | Dec 2027 |
| NCT04887792 | Acetazolamide | Phase 1 | Schizophrenia | Psychiatry | Dec 2027 |
| NCT06717438 | Zatolmilast (BPN14770) | Phase 2 | Jordan's Syndrome | Psychiatry | Dec 2027 |
| NCT06521476 | Acetazolamide | Phase 2 | Central Sleep Apnea Comorbid With Opioid Use | Psychiatry | Feb 2028 |
| NCT06166654 | Acetazolamide | Phase 3 | Acute Heart Failure | Cardiovascular | Mar 2028 |
| NCT05101070 | S-531011 | Phase 1 | Solid Tumors | Oncology | May 2028 |
| NCT05588323 | Naldemedine | Phase 1 | Opioid-Induced Constipation (OIC) | Gastroenterology | Jun 2028 |
| NCT07743580 | Secutrelvir | Phase 3 | SARS-CoV-2 | Infectious disease | Jun 2028 |
| NCT07093580 | S-892216-LAI | Phase 1 | Healthy Participants | Infectious disease | Jun 2028 |
| NCT05953610 | Acetazolamide | Phase 2 | Obstructive Sleep Apnea | Respiratory | Aug 2028 |
| NCT00262470 | Acetazolamide | Phase 1 | Tachycardia | Other | Dec 2029 |
Valenta Pharm JSC Chiesi Farmaceutici Sunshine Lake Pharma Fujian Shengdi Pharmaceutical Shenzhen Salubris Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.